![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment naïve patients with compensated cirrhosis: real-world experience from Taiwan HCV Registry
|
|
|
EASL 2022 June 22-26 London
![0622221](../images/062222/062222-15/0622221.gif)
CH. HUNG1, TS. CHANG2, CF. HUANG3, HT. KUO4, CC. LO5, CW. HUANG6, LW. CHONG7,8, PN. CHENG9, ML. YEH3,10, CY. PENG11,12, CY. CHENG13, JF. HUANG3,14, MJ. BAIR15,16, CL. LIN17, CC. YANG18, SJ. WANG19, TY. HSIEH20, TH. LEE21, PL. LEE22, WC. WU23, CL. LIN24, WW. SU25, SS. YANG26, CC. WANG27, JT. HU28, LR. MO29, CT. CHEN20,30, YH. HUANG31,32, CC. CHANG33,34, CS. HUANG35, GY. CHEN36, CN. KAO37, CM. TAI38,39, CJ. LIU40, MH. LEE41, PC. TSAI3, CY. DAI3, JH. KAO40, HC. LIN31,32, WL. CHUANG3, CY. CHEN42, KC. TSENG43,44, ML. YU3
![0622222](../images/062222/062222-15/0622222.gif)
![0622223](../images/062222/062222-15/0622223.gif)
![0622224](../images/062222/062222-15/0622224.gif)
![0622225](../images/062222/062222-15/0622225.gif)
![0622226](../images/062222/062222-15/0622226.gif)
![0622227](../images/062222/062222-15/0622227.gif)
![0622228](../images/062222/062222-15/0622228.gif)
![0622229](../images/062222/062222-15/0622229.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|